10-year experience in the use of Intravenous Immunoglobulin for Autoimmune Retinopathy

Eye 2026 Open access

Read full text
Authors: A. Abraham, Lina Kobayter, Ester Carreño, Ian Y. L. Yeung, Chrysanthi Tsika, Anthony G. Robson, Rebecca A. Baker, Carlos Eduardo Pavesio, Andrew D. Dick, Colin J. Chu
DOI: 10.1038/s41433-026-04368-6
Cited by: 0
References: 5

Abstract

Autoimmune retinopathies which broadly overlap cancer associated retinopathy and non-paraneoplastic autoimmune retinopathy (npAIR) are complex diagnoses with visually devastating consequences [ 1 ]. There is no consensus on systemic immunosuppression, though a recent meta-analysis of case reports has suggested benefit [ 2 ]. We have seen limited response to classical immunosuppression in our practice and so have historically offered treatment with intravenous immunoglobulin (IVIg) which is commissioned in the UK, and here report on a cohort starting treatment over a 10-year period.

Fields of Study & Subjects

Ocular Diseases and Behçet’s Syndrome Autoimmune Neurological Disorders and Treatments IgG4-Related and Inflammatory Diseases

Publication details

Journal / source
Eye
Volume
40
Issue
7
Pages
1076–1079
Publication date
12 March 2026
Language
EN